Direct Biomarkers of Microbial Translocation Correlate with Immune Activation in Adult Zambians with Environmental Enteropathy and Hepatosplenic Schistosomiasis

Patrick Kaonga,1,2* Evans Kaimoyo,3 Ellen Besa,1 Kanekwa Zymbo,1 Edford Sinkala,5 and Paul Kelly1,6

1Tropical Gastroenterology and Nutrition Group, The University of Zambia School of Medicine, Lusaka, Zambia; 2Department of Internal Medicine, The University of Zambia School of Medicine, Lusaka, Zambia; 3Department of Biological Sciences, The University of Zambia, Lusaka, Zambia; 4Department of Internal Medicine, The University Teaching Hospital, Lusaka, Zambia; 5Department of Internal Medicine, The University Teaching Hospital, Lusaka, Zambia; 6Blizard Institute Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom

Abstract. Microbial translocation is a poorly understood consequence of several disorders such as environmental enteropathy (EE) and hepatosplenic schistosomiasis (HSS). Herein, we compared biomarkers of microbial origin and immune activation in adults with these disorders and in healthy controls. A cross-sectional study was conducted in participants with EE recruited from Misisi compound, Lusaka, Zambia; HSS patients and healthy controls from the University Teaching Hospital, Lusaka. Plasma lipopolysaccharides (LPSs) was measured by limulus amoebocyte lysate assay, plasma 16S ribosomal RNA (16S rRNA) gene copy number was quantified by quantitative real-time polymerase chain reaction, Toll-like receptor ligand (TLRL) activity by QUANTI-Blue detection method, and cytokines from cell culture supernatant by Cytometric Bead Array. In univariate analysis LPS, 16S rRNA gene copy number, and TLR activity were all high and correlated with each other and with cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-10, and IL-4 secreted by the RAW-Blue cells. After controlling for baseline characteristic, biomarkers of microbial translocation in blood were predictors of TNF-α, IL-6, and IL-10 activation in cell culture supernatant from EE participants and HSS patients but not in healthy controls. TLR activity showed the strongest correlation with TNF-α. These data provide correlative evidence that microbial translocation contributes to systemic cytokine activation in two disorders common in the tropics, with total TLR ligand estimation showing the strongest correlation with TNF-α (r = 0.66, P < 0.001).

INTRODUCTION

Microbial translocation (MT) is the passive movement of microbes and/or their products from the gut into mesenteric lymph nodes and other sterile sites. It is common in environmental enteropathy (EE), a subclinical condition hypothesized to be acquired through repeated exposure to fecal–oral contamination.1 EE is characterized by loss of barrier function, chronic intestinal inflammation, MT, and chronic immune activation.2 MT can be measured by detection of direct biomarkers in plasma such as lipopolysaccharide (LPS),3 16S ribosomal RNA (16S rRNA) gene copy number,4 or other pathogen-associated molecular patterns (PAMPs). Hepatosplenic schistosomiasis (HSS) refers to the major complication of chronic infection with Schistosoma mansoni. Schistosoma japonicum, Schistosoma intercalatum, or Schistosoma mekongi. One of the major consequences of HSS disease is portal hypertension, which is associated with esophageal varices or gastric varices or both. Variceal bleeds which result from increased portal pressure may lead to MT.5 In certain parts of rural Zambia prevalence of S. mansoni has reached 77%.6

A recent study in Zambia reported elevated LPS-binding protein (LBP) and soluble CD14 (sCD14), surrogate biomarkers of MT as well as soluble CD163 (sCD163), a biomarker of inflammation in HSS patients compared with healthy controls.7 The optimal measure of MT is not yet established. Previous studies have measured direct biomarkers of MT using LPS8,9 and 16S rRNA gene copy number10,11 without detecting other microbial components which could lead to chronic immune activation and if not controlled may results into microcirculatory dysfunction, septic shock, tissue damage, and mortality.12 We set out to compare three different approaches to measurement of MT in blood samples, by measuring LPS, bacterial DNA, and Toll-like receptor ligand (TLRL) activity, which detects almost all possible PAMPs in plasma including lipoglycans, lipoproteins, lipoteichoic acids, and peptidoglycans.

MATERIALS AND METHODS

Samples and sources. We conducted a cross-sectional study in Misisi compound, which is an unplanned settlement in the southern part of Lusaka city, Zambia, where EE is prevalent.13,14 Eighty-one community adult participants between the ages of 18 and 60 years were recruited after door-to-door sensitization and focus group discussions resulting in their respective consent to participate in the study. Those involved in other studies, or with helminth infection found in stool, pregnant, those on antibiotics or nonsteroidal anti-inflammatory drugs within a month were excluded. EE was confirmed by endoscopy using confocal laser endomicroscopy, followed by binocular microscopy immediately after endoscopy, then formal morphometry of duodenal biopsies after endoscopy, though the degree of EE varied significantly. One hundred and five adult patients recruited from University Teaching hospital with HSS underwent endoscopy. HSS patients were defined by positive serology for schistosomiasis which was done by microwell enzyme-linked immunosorbent assay (ELISA) (Scimedx Corporation, Denville, NJ), hematemesis and/or splenomegaly, and esophageal/gastric varices. The exclusion criteria for HSS patients were inability to give consent, alcohol dependency which was ascertained by questions only, cirrhosis by ultrasound examination, or being seropositive for hepatitis B or C viral infection. We enrolled 65 EE participants, 86 HSS patients, and 40 healthy controls that

* Address correspondence to Patrick Kaonga, Department of Internal Medicine, School of Medicine, The University of Zambia, Nationalist Road, Lusaka 10101. E-mail: patrickkaonga@gmail.com
underwent endoscopic examination and were found to have a normal gut with no HSS disease. The baseline characteristics of study participants are shown (Table 1).

**Blood collection.** Blood was collected from all enrolled participants and centrifuged to extract plasma within 1 hour and stored at −80°C until use.

**Measurement of LPS.** To measure LPS in plasma samples we used the Limulus amebocyte lysate (LAL)-chromo assay (Associates of Cape Cod Incorporated, Falmouth, MA), according to the manufacturer’s instructions.

**Real-time quantitative polymerase chain reaction for measurement of bacterial 16S rRNA in blood.** DNA was isolated from blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The primer pair used was 16S F519 5'-CAG CAGCCCGGTATAAC-3' and 16S R785 5'-GGACTAC CAGGTTATCTAATCC-3', which is specific for conserved DNA sequences encoding the 16S rRNA gene.

The real-time quantitative polymerase chain reaction (PCR) mix consisted of 20 μL SYBR green PCR mix, 0.4 μM of a mixture of both forward and reverse primers at a final concentration of 0.2 mM, 5 μL of DNA, and 4.6 μL endotoxin free water to a final volume of 20 μL. A plasmid DNA with known copy number of template was serially diluted by 10-fold from 1 × 10^6 to 1 × 10^0 copies. The lowest detection limit was 1 × 10^0 copies/μL. PCR was performed using a Rotor gene 6000 thermal cycler (Corbett, North West, Australia); the amplification profile consisted of initial denaturation at 95°C for 15 minutes followed by 40 cycles at 95°C for 15 seconds, 60°C for 20 seconds, and 72°C for 45 seconds. For the specific identification of 16S RNA gene, a melt-curve analysis was conducted by heating PCR products from 65°C to 99°C with continuous acquisition and products were subjected to a ramping profile of 0.2°C/seconds. Ct values of more than 35 cycles were declared as not detected.

**TLR ligand assay using RAW-Blue™ mouse macrophage cell line.** The RAW-Blue mouse macrophage cell line (InvivoGen, San Diego, CA) carries a chromosomal integration of a secreted embryonic alkaline phosphatase (SEAP) reporter gene construct inducible by transcription factors NF-κB and AP-1. Cells were grown on Dulbecco’s Modified Eagle medium as recommended by the supplier, and cell viability was assessed using trypan blue.

To detach confluent cells, they were scraped and resuspended in RAW-Blue test media plated on flat bottom 96-well plate at a density of 1 × 10^5/mL in 180 μL of the test medium and incubated with 20 μL of plasma for 24 hours at 37°C in 5% CO_2 humid atmosphere. After incubation, 50 μL of the cell culture supernatant was incubated with 150 μL of QUANTI-Blue™ detection reagent in a flat bottom 96-well culture plate and then incubated for 1 hour at 37°C. TLR ligand activity (SEAP activity) was determined using a spectrophotometer at 630 nm.

**Analysis of cytokines in RAW-Blue cell culture supernatants.** After 24 hours incubation, cytokines were measured in the cell culture supernatant using a Cytometric Bead Array (CBA) mouse Th1/Th2/Th17 kit (Becton Dickinson, Heidelberg, Germany). The cytokines measured were tumor necrosis factor-α (TNF-α), interleukin (IL)-6 (IL-6), IL-10, IL-4, IL-2, IL-17, and interferon-γ (IFN-γ). Immune activation was defined as cytokine secretion ratio of 2 or more compared with the control supernatant. After acquiring samples on a flow cytometer, FCAP Array™ software (San Jose, CA) was used to analyze results.

**Measurement of other plasma biomarkers of host response to MT.** We used commercially available ELISA kits to measure plasma biomarkers of host immune response to MT (sCD14; [R and D Systems, Inc., Abingdon, UK]; immune activation (C-reactive protein [CRP; R and D Systems]) and soluble (CD163 [sCD163; R and D Systems]).

**Data analysis.** To compare baseline characteristics among EE, HSS patients, and healthy controls, the x^2 test was used for categorical variables and the Kruskal–Wallis test for continuous variables because the D’Agostino–Pearson test showed the data was not normally distributed. Multivariate multiple regression models were constructed to determine whether direct biomarkers were predictors of cytokines while controlling for baseline characteristics with the probability of removal in the final model set at P < 0.20 (20%) and interpreted using regression coefficients and confidence intervals. To understand the relationships among biomarkers and between biomarkers and cytokines, Spearman’s rank correlation was used. All statistical analyses were done using GraphPad Prism, version 5.01 (GraphPad Software Inc., La Jolla, CA) and STATA, version 13 (Stata Corp, College Station, TX). For all statistical tests, a P value < 0.05 was considered statistically significant.

**Ethical consideration.** This study was reviewed and approved by the University of Zambia Biomedical Research and Ethics Committee. Informed written consent was obtained from the participants before participation in the study.

### RESULTS

**Baseline characteristics of study participants.** HSS patients were slightly older than participants in the other two groups (Table 1).

| Variable          | EE group (N = 65) | HSS patients (N = 86) | Healthy controls (N = 41) | P value |
|-------------------|------------------|-----------------------|---------------------------|---------|
| Sex (M:F)¹        | 22:43            | 34:52                 | 20:21                     | 0.41    |
| Age               | 29 (24, 43)      | 40 (30, 51)           | 32 (25, 38)               | 0.01    |
| Education, secondary or more (n, %) ² | 25 (39)          | 33 (38)               | 15 (42)                   | 0.80    |
| BMI (kg/m²)       | 22.9 (20.5, 27.6) | 22.7 (21.4, 26.9)     | 23.6 (21.2, 28.3)         | 0.20    |
| Hb (g/dL)         | 13.3 (12.5, 14.9) | 9.7 (6.4, 11.5)       | 13.6 (11.2, 18.3)         | < 0.001 |
| Platelet count (x10^9/L) | 232 (200, 266) | 121 (87, 137)         | 189 (143, 230)            | < 0.001 |
| White cell count (x10^7/L) | 4.2 (2.8, 4.8) | 2.6 (2.4, 2.1)        | 4 (4, 7)                  | < 0.001 |
| HIV seropositive  | 14 (22)          | 0 (0)                 | 0 (0)                     | < 0.001 |
| CD4 count (cells/μL) | 516 (350, 694) | –                     | –                         | –       |

BMI = body mass index; EE = environmental enteropathy; Hb = hemoglobin; HIV = human immunodeficiency virus; HSS = hepatosplenic schistosomiasis; F = female; M = male.

¹ x^2 was used; percentages are in parentheses. For continuous variables median (interquartile range) are shown.

### Table 1

Baseline characteristics of study participants.
groups, but were more likely to have lower hemoglobin, white cell count, and platelets (Table 1). Participants with EE had a substantial prevalence of human immunodeficiency virus (HIV) (22%; \( P < 0.001 \)) compared with HSS patients and the healthy comparison group of whom none had infection. Other characteristics such as sex, body mass index, education level, and alcohol consumption were comparable (Table 1).

**Direct biomarkers of MT in EE group, HSS patients, and healthy controls.** To compare biomarkers of microbial origin among EE, HSS patients, and healthy controls, we measured LPS, 16S rRNA, and TLR ligand. In univariate analysis, the EE group had significantly higher LPS in plasma (median 378.9 [82.7–879.5] EU/mL) compared with HSS patients (213.1 [77.2–358.3] EU/mL) or healthy controls (202.3 [43.2–251.1] EU/mL) but no difference between HSS patients and healthy controls (Figure 1A). As LPS is only present in gram-negative bacteria, real-time quantitative PCR was used to quantify 16S rRNA gene copy number in blood. 16S rRNA copy number was higher in the EE group (median 2,651 [529–8,779] copies/μL) than the HSS patients (387 [165–1,990] copies/μL; \( P < 0.001 \)) or the healthy controls (193 [132–455] copies/μL; \( P < 0.001 \)) (Figure 1B). The RAW-Blue mouse macrophage cell line was stimulated with plasma to detect total PAMPs activity in plasma. TLRL activity was significantly higher in the EE group (median 0.49 [0.0–0.8] optical density [OD]) than in HSS patients (0.13 [0.0–0.8] OD; \( P = 0.01 \)) or the healthy controls (0.02 [0.0–0.12] OD; \( P = 0.004 \)) (Figure 1C).

**Cytokines in EE group, HSS patients, and healthy controls measured from cell culture supernatants.** Since MT is thought to drive immune activation,3,17–19 we further analyzed the profile of cytokine secretion by the macrophage cells in the EE group and HSS patients compared with healthy controls. To determine whether there were differences in immune activation among groups, we measured TNF-α, IL-6, IL-10, IL-4, IL-2, IFN-γ, and IL-17 produced by stimulated RAW-Blue mouse macrophages.20 Immune activation was defined as a ratio of 2 or more to the secretion under control conditions. In univariate analysis, TNF-α, IL-6, IL-10, and IL-4 were significantly higher in the EE group compared with HSS patients but there was no difference in IL-2. All cytokines were elevated in the EE and HSS groups compared with healthy controls (Figure 2A–E).

**Measurement of host response to MT.** To assess the host response to MT, we analyzed plasma levels of CRP, sCD14, and sCD163. CRP is an acute phase response protein, which is elevated for a short time produced mainly in the liver in response to IL-6.21 We found no difference among all groups in CRP levels (Figure 3A). To assess MT indirectly, we measured the surrogate markers sCD14 and sCD163 in plasma. The EE group had significantly higher sCD14 in plasma (median 1,959 [1,582–2,669] ng/mL) than HSS patients (1,712 [1,389–1,964] ng/mL) or healthy controls (median 1,170 [1,045–1,489] ng/mL; \( P < 0.001 \)) (Figure 3B; \( P < 0.001 \)). sCD163 did not differ between EE group and HSS patients (Figure 3C) but higher levels were found in either group than in healthy controls (\( P < 0.001 \); Figure 3C).

**Relationship between biomarkers of microbial origin and cytokines from the cell culture supernatant.** We next explored the relationship between biomarkers of microbial origin in plasma and cytokines from the cell culture supernatant. With EE and HSS groups combined, TNF-α was positively and strongly correlated with LPS (\( r = 0.61 \); \( P < 0.001 \)), 16S rRNA copy number (\( r = 0.49 \); \( P < 0.001 \)), and TLRL activity (\( r = 0.66 \); \( P < 0.0001 \)) (Supplemental Figure 1A, C, and E). In the healthy controls, TNF-α was not significantly correlated with LPS (\( r = 0.03 \)), 16S rRNA copy number (\( r = 0.22 \)), or TLRL activity

![Figure 1](https://example.com/figure1.jpg)  **Figure 1.** (A) Comparison of lipopolysaccharide, (B) 16S rRNA gene copy number, and (C) Toll-like receptor ligand activity among environmental enteropathy group, hepatosplenic schistosomiasis patients, and healthy controls. Kruskal–Wallis test was used to compare across the groups and Dunns posttest was used to compare all pairs. The results are shown with significance where applicable (\( P < 0.05 \)).
For correlations in the individual groups, EE group had stronger correlation of TNF-α with LPS, 16S rRNA gene copy number, and TLRL activity compared with either HSS patients or healthy controls (data not shown). Generally, combining EE group and HSS participants resulted in increased and more significant correlation of all activated cytokines with direct biomarkers of MT compared with a single group or with healthy controls (Supplemental Figures 1, 2, and 3).

Relationship between biomarkers of microbial origin and biomarkers of host response to MT. In an attempt to explain the differences in biomarkers of microbial origin between EE group or HSS patients and healthy controls, we analyzed the correlation with biomarkers of host response to MT. When groups were analyzed separately, the EE group had generally more significant correlation than HSS patient and healthy controls (Table 2), and when both EE and HSS groups were combined the correlations were stronger. There were no significant correlations in the healthy control group (Table 2).

Multivariable analysis. We constructed multivariate multiple regression models taking LPS, 16S rRNA copy number, and TLRL activity as independent variables and cytokines as dependent variables while controlling for baseline characteristics. In the EE group, a good model fit was obtained ($R^2 = 0.526, F = 47.53, P < 0.001$) which predicted TNF-α, IL-6, and IL-10. In the HSS group, a less impressive but still significant fit was obtained ($R^2 = 0.382, F = 22.43, P = 0.002$); of note in this model LPS did not statistically predict activation of IL-6 and IL-10. In healthy controls, no satisfactory model was obtained ($R^2 = 0.040, F = 1.03, P = 0.38$) (Table 3).

DISCUSSION

There is mounting evidence that MT leads to immune activation in many different disorders, including EE and HSS; it is also a central issue in critical care. It is also difficult to measure. In our study, we asked whether direct biomarkers of MT in plasma correlate with immune activation in EE and HSS.
patients. LPS, present only in gram-negative bacteria, 16S rRNA gene copy number, and TLR ligand (total PAMPs) concentrations in plasma all correlate with immune activation in EE and HSS patients. All of these direct biomarkers of MT were higher in EE individuals compared with HSS patients or healthy controls and were strongly correlated with each other. The levels of direct biomarkers in plasma correlated with biomarkers of the host response to MT such as sCD14 and CD163. In our previous data, we found elevated LPS in EE\textsuperscript{2} and higher sCD14 and sCD163 in HSS patients compared with

**Table 2**

| Variables | LPS | 16S rRNA | TLR | CRP | sCD14 | sCD163 |
|-----------|-----|----------|-----|-----|-------|--------|
| EE group (N = 65) |      |           |     |     |       |        |
| LPS       | 1.0000 |         |     |     |       |        |
| 16S rRNA  | 0.5292** | 1.0000 |     |     |       |        |
| TLR       | 0.4376** | 0.6171** | 1.0000 |     |       |        |
| CRP       | 0.0167 | 0.0477 | 0.0667 | 1.0000 |     |        |
| sCD14     | 0.3734* | 0.0577 | 0.2907* | 0.0708 | 1.0000 |        |
| sCD163    | 0.1154 | 0.1398 | 0.2876* | 0.0722 | 0.2704* | 1.0000 |
| HSS patients (N = 86) |      |           |     |     |       |        |
| LPS       | 1.0000 |         |     |     |       |        |
| 16S rRNA  | 0.5163** | 1.0000 |     |     |       |        |
| TLR       | 0.3932** | 0.6254** | 1.0000 |     |       |        |
| CRP       | 0.1550 | 0.1391 | 0.1737 | 1.0000 |     |        |
| sCD14     | 0.1070 | 0.0157 | 0.2622* | 0.0632 | 1.0000 |        |
| sCD163    | 0.1134 | 0.0996 | 0.2131 | 0.0076 | 0.1285 | 1.0000 |
| Healthy controls (N = 40) |      |           |     |     |       |        |
| LPS       | 1.0000 |         |     |     |       |        |
| 16S rRNA  | 0.0219 | 1.0000 |     |     |       |        |
| TLR       | 0.2093 | 0.0658 | 1.0000 |     |       |        |
| CRP       | 0.1104 | 0.2218 | 0.0756 | 1.0000 |     |        |
| sCD14     | 0.1896 | 0.0615 | 0.0440 | 0.0476 | 1.0000 |        |
| sCD163    | 0.0752 | 0.0018 | 0.1217 | 0.1261 | 0.1329 | 1.0000 |
| EE group and HSS patients combined (N = 151) |      |           |     |     |       |        |
| LPS       | 1.0000 |         |     |     |       |        |
| 16S rRNA  | 0.5231** | 1.0000 |     |     |       |        |
| TLR       | 0.6104** | 0.6404** | 1.0000 |     |       |        |
| CRP       | 0.0407 | 0.2704* | 0.2308* | 1.0000 |     |        |
| sCD14     | 0.3922** | 0.1693 | 0.3112* | 0.10125* | 1.0000 |        |
| sCD163    | 0.2751* | 0.1077 | 0.3126* | 0.0541 | 0.3582** | 1.0000 |

CRP = C-reactive protein; EE = environmental enteropathy; LPS = lipopolysaccharide; 16S rRNA = 16S ribosomal RNA gene; TLR = Toll-like receptor ligand; sCD14 = soluble CD14; sCD163 = soluble CD163. Two-tailed correlations: * P < 0.05, ** P < 0.01.
healthy controls.7 Other studies in chronic HIV infection23,24 suggested that LPS and bacterial DNA are not the onlyTLRLs that can lead to immune activation. In our study, we used in vitro stimulation of RAW-Blue macrophage cells to detect total PAMPs (but not flagellin) to detect other possible biomarkers other than LPS and 16S rRNA that might be involved in MT.

We acknowledge that nearly one quarter of the EE group was HIV positive, but severity of enteropathy in HIV-infected adults is almost indistinguishable (with the exception of crypt depth) from that of uninfected adults with EE.25 Permeability (measured by lactulose:rhamnose ratio) is increased only in acquired immune deficiency syndrome. We excluded cryptosporidiosis and other related opportunistic infection by stool examination in all participants, and in any case diarrhea in the past 2 weeks was an exclusion criterion. In previous work, we observed that plasma LPS concentrations did not differ in HIV-positive patients compared with healthy controls providing further evidence of the host response to MT. CRP is an acute phase protein induced by TNF-α. We also measured several cytokines secreted directly by the RAW-Blue cells. TNF-α is a pro-inflammatory cytokine which leads to reduction in MT.36 We found no difference in CRP among the groups suggesting that it may be a less appropriate biomarker of the activation observed in response to MT.37,38

RAW-Blue cells express all human TLRs except TLR5. We report here the use of TLRL activity to quantify PAMPs in plasma of individuals with EE and HSS patients. TLRL activity has been quantified in stimulated RAW-Blue mouse macrophage cells in diverse contexts together with the pro-inflammatory cytokines such as TNF-α, IL-6, and IL-2.39,41 There are reports that elevated TNF-α leads to reduction in expression of tight junction proteins, such as claudins, resulting in increased MT.42,43 Claudin-2 has been identified as one of the claudin proteins, which is upregulated in stimulated RAW-Blue mouse macrophage cells.44 We also measured several cytokines secreted directly by the RAW-Blue cells. TNF-α is produced by a number of cells including macrophages in response to inflammatory processes.45 In our study, elevated TNF-α seems to correlate more closely with MT than other cytokines. TNF is known to induce an enteropathy.46 As TNF-α can also modulate tight junction proteins, it is possible that MT might be exacerbated by increased levels of circulating TNF-α just as it impairs intestinal barrier function in Crohn’s diseases.47,48 We consider it unlikely that an effect of TNF on tight junctions would alone be sufficient to permit MT as this would probably require a larger, cellular defect in the intestinal barrier.29

### Table 3

|                    | EE (N = 65) | HSS patients (N = 86) | Healthy controls (N = 40) |
|--------------------|------------|----------------------|--------------------------|
|                    | B          | 95% CI               | B                        | 95% CI                  | B                        | 95% CI                  |
| TNF-α              |            |                      |                          |                        |                          |
| LPS                | 0.04       | 0.03 to 0.14**       | 0.06                     | 0.03 to 0.17**         | 0.02                     | -0.09 to 0.13           |
| 16S rRNA           | 0.004      | 0.002 to 0.007**     | 0.006                    | 0.001 to 0.01**        | 0.003                    | -0.007 to 0.01          |
| TLRL               | 11.3       | 6.6 to 15.4**        | 6.1                      | 1.76 to 13.9**         | 3.6                      | -0.95 to 8.45           |
| IL-6               |            |                      |                          |                        |                          |
| LPS                | 0.006      | 0.01 to 0.09**       | 0.09                     | -0.008 to 0.17         | 0.02                     | -0.02 to 0.15           |
| 16S rRNA           | 0.04       | 0.0009 to 0.008*     | 0.01                     | 0.002 to 0.02*         | 0.007                    | -0.001 to 0.02          |
| TLRL               | 7.7        | 2.11 to 9.98**       | 4.5                      | 1.1 to 12.3*           | 1.4                      | -0.5 to 17.3            |
| IL-10              |            |                      |                          |                        |                          |
| LPS                | 0.04       | 0.009 to 0.71*       | 0.03                     | -0.008 to 0.06         | 0.02                     | -0.011 to 0.05          |
| 16S rRNA           | 0.004      | 0.004 to 0.02*       | 0.002                    | 0.0009 to 0.008*       | 0.002                    | -0.003 to 0.004         |
| TLRL               | 1.96       | 0.95 to 4.9*         | 1.4                      | 1.1 to 3.52*           | 0.64                     | -2.2 to 3.5             |
| IL-4               |            |                      |                          |                        |                          |
| LPS                | -0.003     | -0.02 to 0.01        | 0.001                    | -0.002 to 0.003        | 0.0002                   | -0.003 to 0.007         |
| 16S rRNA           | 0.002      | -0.003 to 0.008      | -0.001                   | -0.002 to 0.001        | -0.0001                  | -0.0003 to 0.0006       |
| TLRL               | 1.2        | -1.6 to 4.1          | -3.1                     | -9.5 to 3.2            | -0.8                     | -0.22 to 0.07           |
| IL-2               |            |                      |                          |                        |                          |
| LPS                | -0.001     | -0.007 to 0.005      | -0.002                   | -0.01 to 0.007         | 0.002                    | -0.01 to 0.008          |
| 16S rRNA           | -0.005     | -0.01 to 0.01        | -0.006                   | -0.007 to 0.009        | -0.0001                  | -0.008 to 0.001         |
| TLRL               | 0.46       | -0.75 to 1.67        | -1.5                     | -4.1 to 3.7            | -0.02                    | -0.1 to 0.08            |

**B = beta coefficient; CI = confidence interval; CRP = C-reactive protein; EE = environmental enteropathy; HSS = hepatosplenic schistosomiasis; IL-2 = interleukin; LPS = lipopolysaccharide; TLRL = Toll-like receptor ligand; TNF-α = tumor necrosis factor-α; sCD14 = soluble CD14; sCD163 = soluble CD163; WBC = white blood cell; 16S rRNA = 16S ribosomal RNA gene. Data are given as regression coefficient (B) and 95% CI. R2 is 0.526 for the EE model, 0.382 for the HSS model, and 0.040 for the healthy controls model. Outcome variables were log-transformed and reported back on the original scale of measurement.

* P < 0.001 significant values different from reference category adjusted for all explanatory variables in the model, age, hemoglobin, platelet, WBC, and HIV.

** P < 0.01 significant values different from reference category adjusted for all explanatory variables in the model, age, hemoglobin, platelet, WBC, and HIV.
We found higher levels of IL-6 in EE than in HSS patients or healthy controls and it correlated with biomarkers of MT. In a mouse model, treatment with a monoclonal antibody to IL-6 resulted in reduced intestinal permeability and reduced the expression of claudin-2 suggesting that suppression of IL-6 promotes intestinal barrier integrity. In IBDs, it has been suggested that IL-6 increases tight junction permeability through the mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphoinositide 3-kinase pathways in intestinal epithelial cells by stimulating the expression of channel-forming claudin-2. Other studies have reported that increased IL-6 correlates with diseases severity in Crohn’s disease. We found that IL-10 was higher in the EE group compared with HSS patients or healthy controls. IL-10 is an immunomodulatory cytokine with potent anti-inflammatory properties and IL-10 treatment in IBDs has shown successful results in many mouse models. In human, a double-blind, placebo-controlled study was conducted to investigate the efficacy and safety of IL-10 treatment in patients with Crohn’s disease. The overall findings showed only trivial and nonsignificant clinical improvement. In a macaque model, a study was set out to characterize the pathogenesis of HIV-mediated enteropathy and demonstrated increased production of IL-10 was accompanied by disruption of epithelial barrier as evidenced by loss of ZO-1 and was associated with up regulation of mucosal TNF-α and IFN-γ suggesting that IL-10 was unable to turn down inflammatory response. Perhaps surprisingly, although studies have reported IL-10 inhibits secretion of pro-inflammatory cytokines, others have reported that IL-10 has the ability to stimulate T cells, B cells, and NK cells which can result in establishment of inflammation. MT could lead to immune activation followed by generalized and persistent chronic inflammation and immune activation as reported elsewhere, but a full explanation of the role of individual cytokines is not yet available in EE and HSS patients.

In conclusion, we found higher levels of plasma LPS, 16S rRNA, and TLRL in individuals with EE compared with HSS patients or healthy control. Plasma sCD14 and sCD163 were also elevated in EE compared with HSS patients or controls. In both EE and HSS patients, the correlation of direct biomarkers with immune activation measured by TNF-α, IL-16, and IL-10 was significant. These data are in line with a model that biomarkers of microbial origin in the gastrointestinal tract move across a compromised intestinal barrier in EE and HSS patients, inducing systemic immune activation.

Received May 8, 2017. Accepted for publication June 12, 2017.

Note: Supplemental figures appear at www.ajtmh.org.

Acknowledgments: We are grateful to Gershorn Chongwe for statistical advice and Derick Munkombwe for helpful comments on this manuscript.

Financial support: This work was supported by the Bill & Melinda Gates Foundation (grant no. OPP1066118) and the Wellcome Trust SACORE consortium (grant no. 087537).

Authors’ addresses: Patrick Kaonga, Tropical Gastroenterology and Nutrition Group, The University of Zambia School of Medicine, Lusaka, Zambia, and Department of Internal Medicine, The University of Zambia School of Medicine, Lusaka, Zambia, E-mail: patrickkaonga@gmail.com. Evans Kaimoyo, Department of Biological Sciences, School of Natural Sciences, The University of Zambia, Great East Road, Lusaka, Zambia, E-mail: ekaimoyo@gmail.com. Ellen Besa and Kanekwa Z Yangombo, Tropical Gastroenterology and Nutrition Group, The University of Zambia School of Medicine, Nationalist Road, Lusaka, Zambia, E-mails: chibutabesa@gmail.com and kanbzyangombo@gmail.com; Edford Sinkala, Department of Internal Medicine, The University Teaching Hospital, Lusaka, Zambia, E-mail: sinkalaeddie@yahoo.com. Paul Kelly, Tropical Gastroenterology and Nutrition Group, The University of Zambia School of Medicine, Lusaka, Zambia, and Blizard Institute Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom, E-mail: m.p.kelly@qmul.ac.uk.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Korpe PS, Petri WA. 2012. Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 18: 328–336.
2. Kelly P, Besa E, Zyangombo K, Louis-Auguste J, Lees J, Banda T, Soko R, Banda R, Arnadi B, Watson A, 2016. Endoscopic and transcriptomic analysis of impaired barrier function and malabsorption in environmental enteropathy. PLoS Negl Trop Dis 10: e0004600.
3. Campbell DI, Murch SH, Elia M, Sullivan PB, Sanyang MS, Jobarteh B, Lunn PG, 2003. Chronic T cell-mediated enteropathy in rural West African children: relationship with nutritional status and small bowel function. Pediatr Res 54: 306–311.
4. Yu J, Ordiz M, Stauber J, Shaikh N, Trehan I, Barnett E, Head RD, Maleta K, Tarr PI, Manary MJ, 2016. Environmental enteric dysfunction includes a broad spectrum of inflammatory responses and epithelial repair processes. Cell Mol Gastroenterol Hepatol 2: 158–174.e1.
5. Vlaichogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD, 2013. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28: 450–455.
6. Muteng MM, Mwansa JCL, Mdluluza T, Sianongo S, Chipeta J, 2014. High Schistosoma mansoni disease burden in a rural district of western Zambia. Am J Trop Med Hyg 91: 956–972.
7. Sinkala E, Kapulu MC, Besa E, Zyangombo K, Chioso NJ, Foster GR, Kelly P, 2016. Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. Liver Int 36: 145–150.
8. Kelly P, Besa E, Lees J, Banda T, Zyangombo K, Muchimba M, Watson A, Louis-Auguste J, 2015. PTH-231 pathways of epithelial leakage and zinc malabsorption in environmental enteropathy imaged by confocal endomicroscopy. Gut 64: A511–A512.
9. Uddin MI, Islam S, Nishtat NS, Hossain M, Rafique TA, Rasu R, Hoq MR, Zhang Y, Saha A, Harris JB, 2016. Biomarkers of environmental enteropathy are positively associated with immune responses to an oral cholera vaccine in Bangladeshi children. PLoS Negl Trop Dis 10: e0005039.
10. Kramski M, Gaeguta AJ, Gutierrez C, Madrid N, Munoz MA, Moreno S, 2013. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals. J Acquir Immune Defic Syndr 64: 149–153.
11. Abad-Fernandez M, Vallejo A, Hernandez-Novoa B, Diaz L, Guitierrez C, Madrid N, Munoz MA, Moreno S, 2013. Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals. J Acquir ImmuneDefic Syndr 64: 149–153.
12. Ulevitch RJ, Tobias PS, 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13: 437–457.
13. Kelly P, et al., 2004. Responses of small intestinal architecture and function over time to environmental factors in a tropical population. Am J Trop Med Hyg 70: 412–419.
14. Louis-Auguste J, Greenwald S, Simuyandi M, Soko R, Banda R, Kelly P, 2014. High dose multiple micronutrient supplementation.
improves villous morphology in environmental enteropathy with- out HIV enteropathy: results from a double-blind randomised placebo controlled trial in Zambian adults. BMC Gastroenterol 14: 1–10.

15. Wadouvie A, Van der Auwera G, De Wachter R, 1993. Structure of the 16 S ribosomal RNA of the thermophilic cyanobacterium Chlorogloeopsis HTF (‘Mastigocladus laminosus HTF’) strain PCC7518, and phylogenetic analysis. FEBS Lett 371: 96–100.

16. Dittmar R, Potier E, van Zandvoort M, Ito K, 2012. Assessment of cell viability in three-dimensional scaffolds using cellular auto- fluorescence. Tissue Eng Part C Methods 18: 198–204.

17. Turner JR, 2009. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799–809.

18. Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulze JD, 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56: 61–72.

19. Marchetti G, et al., 2011. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naïve patients with high CD4+ cell count. AIDS 25: 1385–1394.

20. Yoon S-B, Lee Y-J, Park SK, Kim H-C, Bae H, Kim HM, Ko S-G, Choi HY, Oh MS, Park W, 2009. Anti-inflammatory effects of Scurtellania baikalensis water extract on LPS-activated RAW 264.7 macrophages. J Ethnopharmacol 125: 286–290.

21. Dungey M, Hull KL, Smith AC, Burton JO, Bishop NC, 2013. Inflammatory factors and exercise in chronic kidney disease. Int J Endocrinol 2013: 12.

22. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, de la Hera Riggio O, Ridola L, Aagaard NK, Moller HJ, Vilstrup H, 2011. Enteropathies in the developing macaques recapitulates important features of pathogenic SIV infection. Annals of the New York Academy of Sciences 1241: 61–81.

23. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE, 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85: 1139–1162.

24. Chiba H, Kojima T, Otsani M, Sawada N, 2006. The significance of interferon-γ-triggered internalization of tight-junction proteins in inflammatory bowel disease. Sci STKE 2006; pr1.

25. Walsh SV, Hopkins AM, Nussat A, 2000. Modulation of tight junction structure and function by cytokines. Adv Drug Deliv Rev 41: 303–313.

26. Szliszka E, Mertas A, Czuba ZP, Król W, 2013. Inhibition of inflammatory response by Artepillin C in activated RAW264.7 macrophages. Evid Based Complement Alternat Med 2013: 735176.

27. Garside P, Bunce C, Tomlinson RC, Nichols BL, Mowat AM, 1993. Analysis of entropathy induced by tumour necrosis factor α. Cytokine 5: 24–30.

28. Kaser A, Ludwiczek O, Waldemarperger B, Jaschke W, Vogel W, Tilg H, 2002. Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting. Liver 22: 380–387.

29. Tilg H, Moschen AR, Kaser A, 2009. Obesity and the microbiota. Gastroenterology 136: 1476–1483.

30. Xiao Y-T, Yan W-H, Cao Y, Yan J-K, Cai W, 2016. Neutralization of IL-6 and TNF-α ameliorates intestinal permeability in DSS-induced colitis. Cytokine 83: 189–192.

31. Suzuki T, Yoshinaga N, Tanabe S, 2011. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem 286: 31263–31271.

32. Funderburg NT, et al., 2013. Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 140: 87–97.

33. Kessler B, Rinchai D, Kewcharoenwong C, Nithichanon A, Biggart JV, 2007. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology 133: 878–890.

34. Sandler NG, et al., 2011 Plasma levels of soluble CD14 are independently predict mortality in HIV infection. J Infect Dis 203: 780–790.

35. Shrivastava AK, Singh HV, Raizada A, Singh SK, 2015. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J 67: 89–97.

36. Elbaz T, Esmat G, 2013. Hepatic and intestinal schistosomiasis. Review. J Adv Res 4: 445–452.

37. Kosek M, et al., 2014. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. Nephrol Dial Transplant 59: S239–S247.

38. Zhou HF, et al., 2011. Biflavonoids from Caper (Capparis spinosa L.) fruits and their effects in inhibiting NF-κappa B activation. J Agric Food Chem 59: 3060–3065.

39. Lewis RE, Liao G, Young KL, Douglas C, 2014. Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother 58: 1738–1743.

40. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE, 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85: 1139–1162.

41. Lewis RE, Liao G, Young KL, Douglas C, 2014. Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother 58: 1738–1743.

42. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE, 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85: 1139–1162.

43. Lewis RE, Liao G, Young KL, Douglas C, 2014. Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob Agents Chemother 58: 1738–1743.